CD44 and neoplasm: Importantly, the “GP@Gel Nap‐T” group leaded to the highest percentages of TCM (CD44+CD62L+) and TEM (CD44+CD62L−) cells in CMT167 tumor tissues and TDLNs, suggesting that GP@Gel Nap‐T not only enhanced the immediate antitumor immune response but also provided long‐term protection against tumor burdens, metastasis, or relapse.